Aila Biotech uses a patented gene‑delivery platform to introduce DNA constructs that produce immune‑regulating biologics directly within affected neural tissue. This enables spatially and temporally controlled therapeutic protein expression, providing localized modulation of neuroinflammatory diseases while minimizing systemic exposure. The technology is aimed at pharmaceutical, biotech, and research partners developing treatments for conditions such as multiple sclerosis, traumatic brain injury, and post‑COVID neurological complications.
Funding
Funding not disclosed
Founders
Product
Problem
Neuroinflammatory diseases such as multiple sclerosis, traumatic brain injury, and post‑COVID neurological complications involve uncontrolled immune activity that damages neural tissue. Current systemic therapies often lack precise targeting, leading to limited efficacy and systemic side effects.
Solution
Aila Biotech employs a patented gene‑delivery platform that introduces DNA constructs encoding immune‑regulating biologics directly into the affected neural tissue. The system provides spatially confined and temporally controllable expression of therapeutic proteins, enabling localized modulation of the immune response while minimizing systemic exposure. By delivering biologics at the site of disease, the platform aims to halt or reverse neuroinflammatory damage and slow disease progression. The approach is designed for integration into clinical protocols as an adjunct or alternative to conventional systemic immunotherapies, offering clinicians a tool to tailor immune modulation to individual patient pathology.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for neuroinflammatory disorders, as well as academic and clinical research groups conducting translational studies in neuroimmunology.
Features
- Patented viral or non‑viral vector engineered for targeted transduction of central nervous system cells
- Controlled promoter systems that allow inducible or time‑limited expression of therapeutic proteins
- Capability to deliver a range of immune‑regulating biologics (e.g., cytokine antagonists, checkpoint modulators) from a single platform
- In‑situ production of therapeutics reduces dosing frequency and systemic drug burden
- Preclinical validation demonstrating reduction of neuroinflammatory markers and preservation of neural tissue